The other patient (Patient 22) had a de novo AML without cytogenetic anomaly, and the mutations detected at the time of relapse (FLT3-TKD, NPM1, WT1) have not been considered molecular markers of an unfavorable prognosis [50]. The gene discussed is NPM1; the disease is acute myeloid leukemia.